JPH06503467A - 上皮増殖因子受容体に関連する受容体のための遺伝子をコードしているdnaセグメント - Google Patents
上皮増殖因子受容体に関連する受容体のための遺伝子をコードしているdnaセグメントInfo
- Publication number
- JPH06503467A JPH06503467A JP3500885A JP50088591A JPH06503467A JP H06503467 A JPH06503467 A JP H06503467A JP 3500885 A JP3500885 A JP 3500885A JP 50088591 A JP50088591 A JP 50088591A JP H06503467 A JPH06503467 A JP H06503467A
- Authority
- JP
- Japan
- Prior art keywords
- erbb
- dna
- human
- amino acid
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Abstract
Description
Claims (20)
- 1.erbB−3遺伝子またはその特異的部分をコードしているヌクレオチド配 列を持つDNAセグメント。
- 2.該遺伝子が哺乳動物のerbB−3遺伝子である請求項1記載のDNAセグ メント。
- 3.該哺乳動物のerbB−3遺伝子がヒトのerbB−3遺伝子である請求項 2記載のDNAセグメント。
- 4.ゲノムのDNA断片である、ヌクレオチド配列またはその特異的部分を持つ DNAセグメントであって;SacI制限酸素による切断により生成し、約9k bpの大きさを持ち、そしてレジユーズド・ストリンジェンシ−(reduce d stringency)ハイブリッド形成の条件下でのみv−erbB遺伝 子から誘導されたプローブを使用する核酸ハイブリッド形成により検出できるD NAセグメント。
- 5.該セグメントがヒトゲノムのDNAクローンE3−1、その特異的部分であ り、そして該クローンが図2で定義した部分的制限酵素地図と図3で定義した部 分的制限配列を持っている請求項4記載のDNAセグメント。
- 6.該ヌクレオチド配列が、erbB−3遺伝子のまたはその特異的部分のアミ ノ酸配列をコードしている請求項1記載のDNAセグメント。
- 7.該アミノ酸配列が図4で定義したそれである請求項6記載のDNAセグメン ト。
- 8.図4で定義したヌクレオチド配列を持つヒトcDNAクローンE3−16を 含有する請求項7記載のDNAセグメント。
- 9.ヒトerbB−3の、またはその特異的部分のアミノ酸配列と少なくともア ミノ酸一個分が異なるアミノ酸配列をコードし、そして他の如何なるポリペプチ ドのアミノ酸配列よりも、ヒトerbB−3のアミノ酸配列に全体的相同性をよ り大に持つDNAセグメント。
- 10.ヒトerbB−3ポリペプチドの機能を実質的に持つアミノ酸配列をコー ドしている請求項9記載のDNAセグメント。
- 11.請求項9記載のDNAセグメントによりコードされているアミノ酸配列を 持つ単擁したポリペプチド。
- 12.請求項1記載のDNAセグメントとベクターを含有する組換えDNA分子 。
- 13.請求項1記載のDNAセグメントで形質転換した細胞の培養物。
- 14.図4で定義したアミノ酸配列、またはその特異的部分を持つ単離したポリ ペプチド。
- 15.生物試料中のerbB−3mRNAを検出するための生物学的検定法であ って; i)請求項1記載のDNAセグメントに生物試料を、該DNAセグメントと相補 的RNAを含有するDNA:RNAハイブリッド分子が形成され得るような条件 下で、接触させ;次いで ii)該ハイブリッド分子中に存在する該DNAセグメントの量を決定する段階 からなることを特徴とする検定法。
- 16.erbB−3受容体により媒介される活性に影響する能力を、該erbB −3受容体のリガントとして可能性のある同族体について試験するための生物学 的検定法であって; i)請求項11記載の細胞により生産されるerbB−3受容体を、リガントで あると疑われている分子と接触させ;そして ii)該細胞中の該erbB−3受容体により媒介された生物学的活性の量を測 定する段階からなることを特徴とする生物学的検定法。
- 17.請求項14記載のポリペプチドの特異的部分に特異的である抗体。
- 18.生物学試料中のerbB−3抗原を検出するための生物学的検定法であっ て; i)請求項17記載の抗体に該試料を、該抗体と該抗原の特異的複合体が形成で きるような条件下で、接触させ;そして ii)該複合体として存在する該抗体の量を決定する段階からなることを特徴と する検定法。
- 19.治療用薬物の標的を、erbB−3受容体を高レベルで持つ細胞にする方 法であって;i)請求項17記載の抗体を、またはその活性断片をを、該薬物に 接合させ;そして ii)得られた接合体を、erbB−3受容体を高レベルで持つ細胞を持つ個体 に、有効量でかつ該抗体が該細胞上の該受容体上に結合できるような有効な方法 で、投与する段階なることを特徴とする方法。
- 20.治療用薬物の標的をerbB−3受容体を高レベルで持つ細胞にするため に、該治療用薬物に接合した請求項17記載の抗体、またはその活性断片を使用 する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/444,406 US5183884A (en) | 1989-12-01 | 1989-12-01 | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US444,406 | 1989-12-01 | ||
PCT/US1990/007025 WO1991008214A1 (en) | 1989-12-01 | 1990-11-30 | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001085000A Division JP3632171B2 (ja) | 1989-12-01 | 2001-03-23 | erbB−3ポリペプチドをコードするDNAセグメント、前記ポリペプチドを検出するための抗体及びバイオアッセイ |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06503467A true JPH06503467A (ja) | 1994-04-21 |
JP3196079B2 JP3196079B2 (ja) | 2001-08-06 |
Family
ID=23764745
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50088591A Expired - Lifetime JP3196079B2 (ja) | 1989-12-01 | 1990-11-30 | 上皮増殖因子受容体に関連する受容体のための遺伝子をコードしているdnaセグメント |
JP2001085000A Expired - Lifetime JP3632171B2 (ja) | 1989-12-01 | 2001-03-23 | erbB−3ポリペプチドをコードするDNAセグメント、前記ポリペプチドを検出するための抗体及びバイオアッセイ |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001085000A Expired - Lifetime JP3632171B2 (ja) | 1989-12-01 | 2001-03-23 | erbB−3ポリペプチドをコードするDNAセグメント、前記ポリペプチドを検出するための抗体及びバイオアッセイ |
Country Status (10)
Country | Link |
---|---|
US (6) | US5183884A (ja) |
EP (1) | EP0502927B1 (ja) |
JP (2) | JP3196079B2 (ja) |
AT (1) | ATE163970T1 (ja) |
AU (1) | AU654805B2 (ja) |
CA (1) | CA2069900C (ja) |
DE (1) | DE69032133T2 (ja) |
DK (1) | DK0502927T3 (ja) |
ES (1) | ES2113877T3 (ja) |
WO (1) | WO1991008214A1 (ja) |
Families Citing this family (182)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0474727T3 (da) * | 1989-05-19 | 1998-01-12 | Genentech Inc | HER2 ekstracellulært domæne |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US5578482A (en) * | 1990-05-25 | 1996-11-26 | Georgetown University | Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses |
US5776755A (en) * | 1992-10-09 | 1998-07-07 | Helsinki University Licensing, Ltd. | FLT4, a receptor tyrosine kinase |
US6824777B1 (en) | 1992-10-09 | 2004-11-30 | Licentia Ltd. | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
US6107046A (en) * | 1992-10-09 | 2000-08-22 | Orion Corporation | Antibodies to Flt4, a receptor tyrosine kinase and uses thereof |
US5811098A (en) * | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
JPH09503381A (ja) * | 1993-07-09 | 1997-04-08 | ジ・インスティテュート・オブ・キャンサー・リサーチ | プロテインチロシンキナーゼ及びそのリガンド |
JP4145953B2 (ja) | 1993-10-27 | 2008-09-03 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | Mda−7遺伝子 |
US5518885A (en) * | 1994-04-19 | 1996-05-21 | The United States Of America As Represented By The Department Of Health & Human Services | ERBB2 promoter binding protein in neoplastic disease |
US7175995B1 (en) | 1994-10-27 | 2007-02-13 | Thomas Jefferson University | TCL-1 protein and related methods |
US5985598A (en) * | 1994-10-27 | 1999-11-16 | Thomas Jefferson University | TCL-1 gene and protein and related methods and compositions |
US5635351A (en) * | 1995-03-14 | 1997-06-03 | The Regents Of The University Of California | Genetic gain and loss in gliomas |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5968511A (en) * | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
DK0896586T4 (en) * | 1996-03-27 | 2015-08-24 | Genentech Inc | ErbB3 antibodies. |
IL127891A0 (en) | 1996-07-12 | 1999-10-28 | Genentech Inc | Chimeric heteromultimeter adhesins |
IL127892A0 (en) * | 1996-07-12 | 1999-10-28 | Genentech Inc | Gamma-heregulin |
US5710137A (en) | 1996-08-16 | 1998-01-20 | The Trustees Of Columbia University In The City Of New York | Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype |
US7371376B1 (en) * | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
US6136558A (en) * | 1997-02-10 | 2000-10-24 | Genentech, Inc. | Heregulin variants |
ATE427353T1 (de) | 1997-02-10 | 2009-04-15 | Genentech Inc | Heregulin varianten |
ATE323756T1 (de) * | 1997-04-30 | 2006-05-15 | Hans Klingemann | Natürliche killerzelllinien und verfahren zu ihrer verwendung |
US7052692B1 (en) | 1997-09-02 | 2006-05-30 | Advanced Research & Technology Institute | Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression |
EP2033970A3 (en) | 1997-10-29 | 2009-06-17 | Genentech, Inc. | Polypeptides and nucleic acids encoding the same |
US6387657B1 (en) | 1997-10-29 | 2002-05-14 | Genentech, Inc. | WISP polypeptides and nucleic acids encoding same |
ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
US20010023241A1 (en) * | 1998-02-04 | 2001-09-20 | Sliwkowski Mark X. | Use of heregulin as a growth factor |
EP1941905A1 (en) | 1998-03-27 | 2008-07-09 | Genentech, Inc. | APO-2 Ligand-anti-her-2 antibody synergism |
EP1119371B1 (en) * | 1998-10-09 | 2010-11-24 | Vegenics Limited | Flt4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY |
DK1165113T3 (da) * | 1999-04-06 | 2008-09-08 | Genentech Inc | Anvendelse af ErbB-receptorligander i behandling af diabetes |
AUPQ105799A0 (en) * | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
US20030086924A1 (en) * | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
WO2001000238A1 (en) * | 1999-06-25 | 2001-01-04 | Genentech, Inc. | TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES |
AU784157B2 (en) | 1999-06-25 | 2006-02-16 | Genentech Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
HU226742B1 (en) | 1999-06-25 | 2009-08-28 | Genentech Inc | Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies |
US20040013667A1 (en) * | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
NZ517150A (en) | 1999-08-27 | 2005-01-28 | Genentech Inc | Dosages for treatment with anti-ErbB2 antibodies |
US7390632B2 (en) * | 1999-09-30 | 2008-06-24 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 receptor isoforms |
US7892541B1 (en) | 1999-09-30 | 2011-02-22 | Tumor Biology Investment Group, Inc. | Soluble epidermal growth factor receptor isoforms |
WO2001024763A2 (en) | 1999-10-01 | 2001-04-12 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
LT2857516T (lt) | 2000-04-11 | 2017-09-11 | Genentech, Inc. | Multivalentiniai antikūnai ir jų panaudojimas |
WO2001083781A2 (en) * | 2000-04-28 | 2001-11-08 | Millennium Pharmaceuticals, Inc. | 14094, a novel human trypsin family member and uses thereof |
PL400669A1 (pl) * | 2000-05-19 | 2012-11-05 | Genentech, Inc. | Genowa próba wykrywania odpowiedzi na antagoniste ErbB dla poprawienia prawdopodobienstwa i skutecznosci leczenia raka |
CN1204142C (zh) * | 2000-06-01 | 2005-06-01 | 冯宝章 | 反基因V-erbB寡核苷酸及其应用 |
US6277640B1 (en) | 2000-07-31 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Antisense modulation of Her-3 expression |
US20020119148A1 (en) * | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
EP1332368A2 (en) * | 2000-11-03 | 2003-08-06 | Board of Regents, The University of Texas System | Methods for detecting the efficacy of anticancer treatments |
AU2002248372B8 (en) * | 2001-01-19 | 2008-03-20 | Vegenics Limited | FLT4(VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
EP1228766A1 (en) * | 2001-01-31 | 2002-08-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PYK2 phosphorylation by HER3 induces tumor invasion |
WO2002081649A2 (en) * | 2001-04-06 | 2002-10-17 | The Trustees Of The University Of Pennsylvania | ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF |
WO2002088363A2 (en) * | 2001-05-02 | 2002-11-07 | Bayer Healthcare Ag | Regulation of novel human prolyl 4-hydroxylases |
US7745398B2 (en) * | 2001-05-31 | 2010-06-29 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 and treatment of cancer |
US7744882B2 (en) | 2001-05-31 | 2010-06-29 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 methods of detection and antibodies |
US7638302B2 (en) * | 2001-05-31 | 2009-12-29 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 receptor isoforms |
DE10131187C2 (de) * | 2001-06-28 | 2003-06-18 | Infineon Technologies Ag | Belichtungsmaske mit reparierter Blindstruktur |
WO2003011897A1 (en) | 2001-07-27 | 2003-02-13 | The Regents Of The University Of California | Modulation of heregulin and her3 interaction |
EP1283053A1 (en) * | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
AU2002326910A1 (en) * | 2001-09-14 | 2003-04-01 | Incyte Genomics, Inc. | Receptors and membrane-associated proteins |
JP2003110360A (ja) * | 2001-09-28 | 2003-04-11 | Seiko Epson Corp | 電圧制御型発振器、受信装置および通信装置 |
CA2480099C (en) * | 2002-03-26 | 2019-01-08 | Zensun (Shanghai) Sci-Tech. Ltd. | Erbb3 based methods and compositions for treating neoplasms |
US20040229294A1 (en) | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
US7402397B2 (en) | 2002-05-21 | 2008-07-22 | Monogram Biosciences, Inc. | Detecting and profiling molecular complexes |
US20040229380A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB heterodimers as biomarkers |
CA2490542C (en) | 2002-05-23 | 2013-07-16 | Mark I. Greene | Fas peptide mimetics and uses thereof |
JP5069843B2 (ja) | 2002-07-15 | 2012-11-07 | ジェネンテック, インコーポレイテッド | 抗ErbB2抗体を用いる処置に応答性である腫瘍を同定するための方法 |
US8505468B2 (en) * | 2002-11-19 | 2013-08-13 | Sharp Kabushiki Kaisha | Substrate accommodating tray |
JP2006516117A (ja) * | 2002-11-21 | 2006-06-22 | ジェネンテック・インコーポレーテッド | 抗ErbB2抗体を用いた非悪性疾病または疾患の治療 |
AU2004225439A1 (en) | 2003-04-01 | 2004-10-14 | Monogram Biosciences, Inc. | Intracellular complexes as biomarkers |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
JP2007525187A (ja) * | 2003-05-16 | 2007-09-06 | レセプター・バイオロジクス・インコーポレイテッド | イントロン融合タンパク質、ならびにその同定方法および使用方法 |
US7402398B2 (en) * | 2003-07-17 | 2008-07-22 | Monogram Biosciences, Inc. | Measuring receptor homodimerization |
EP1673399B1 (en) * | 2003-08-11 | 2017-04-05 | Monogram BioSciences, Inc. | Detecting and profiling molecular complexes |
EP1681983A4 (en) * | 2003-10-14 | 2008-12-10 | Monogram Biosciences Inc | RECEPTOR TYROSINE KINASE SIGNAL PATH ANALYSIS FOR DIAGNOSIS AND THERAPY |
BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
CA2563341C (en) * | 2004-04-08 | 2014-10-21 | David B. Agus | Erbb antagonists for pain therapy |
WO2005113596A2 (en) * | 2004-05-14 | 2005-12-01 | Receptor Biologix, Inc. | Cell surface receptor isoforms and methods of identifying and using the same |
BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
GT200500155A (es) * | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
JP2008507520A (ja) * | 2004-07-22 | 2008-03-13 | ジェネンテック・インコーポレーテッド | Her2抗体組成物 |
RU2412947C2 (ru) | 2004-09-23 | 2011-02-27 | Дженентек, Инк. | Антитела, сконструированные на основе цистеинов, и их конъюгаты |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US7939267B2 (en) * | 2004-11-04 | 2011-05-10 | Laboratory Corporation Of America Holdings | Detection of activation of endothelial cells as surrogate marker for angiogenesis |
AU2005314127A1 (en) * | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a HER inhibitor |
KR20190110637A (ko) | 2005-01-21 | 2019-09-30 | 제넨테크, 인크. | Her 항체의 고정 용량 투여법 |
KR20070100968A (ko) * | 2005-02-09 | 2007-10-15 | 제넨테크, 인크. | 매트릭스 메탈로프로테아제 길항제를 사용한, her2박리의 억제 |
RU2404806C2 (ru) * | 2005-02-23 | 2010-11-27 | Дженентек, Инк. | Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her |
US20060204505A1 (en) * | 2005-03-08 | 2006-09-14 | Sliwkowski Mark X | Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs) |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
US20090170769A1 (en) * | 2005-05-13 | 2009-07-02 | Pei Jin | Cell surface receptor isoforms and methods of identifying and using the same |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
DK2511301T3 (en) | 2006-08-04 | 2018-03-12 | Medimmune Ltd | HUMAN ANTIBODIES AGAINST ERBB 2 |
EP2097754B2 (en) * | 2006-11-28 | 2018-01-24 | Daiichi Sankyo Europe GmbH | Activated her3 as a marker for predicting therapeutic efficacy |
EP3248617A3 (en) | 2007-02-16 | 2018-02-21 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
PE20090681A1 (es) | 2007-03-02 | 2009-06-10 | Genentech Inc | Prediccion de respuesta a un inhibidor her |
KR101540822B1 (ko) | 2007-03-27 | 2015-07-30 | 씨 레인 바이오테크놀로지스, 엘엘씨 | 항체 대용물 경쇄 서열을 포함하는 구축물 및 라이브러리 |
WO2008154249A2 (en) | 2007-06-08 | 2008-12-18 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
WO2009070772A1 (en) * | 2007-11-27 | 2009-06-04 | Monogram Biosciences, Inc. | Enhanced method for detecting and/or quantifying an analyte in a sample |
EP2235536A4 (en) * | 2007-12-20 | 2011-05-04 | Lab Corp America Holdings | HER-2 DIAGNOSTIC METHODS |
BRPI0822012A2 (pt) | 2008-01-18 | 2015-07-21 | Natco Pharma Ltd | Derivados de quinazolina de 6,7-dialcóxi úteis para o tratamento de distúrbios relacionados com câncer |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
ES2629405T3 (es) | 2008-03-18 | 2017-08-09 | Genentech, Inc. | Combinaciones de un conjugado de fármaco-anticuerpo anti-HER2 y docetaxel |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
WO2009157919A1 (en) * | 2008-06-23 | 2009-12-30 | Tumor Biology Investment Group, Inc. | SOLUBLE ErbB3 DETECTION, REGULATION AND TREATMENT OF CANCER |
UA104868C2 (uk) * | 2008-08-15 | 2014-03-25 | Меррімак Фармасьютікалз, Інк. | Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції |
CA2764386C (en) | 2008-12-01 | 2018-05-01 | Laboratory Corporation Of America Holdings | P95-her2 antibodies and uses thereof |
WO2010083470A1 (en) | 2009-01-15 | 2010-07-22 | Laboratory Corporation Of America Holdings | Methods of determining patient response by measurement of her-3 |
TW201544123A (zh) | 2009-03-20 | 2015-12-01 | Genentech Inc | 抗-her抗體 |
EP2425009A4 (en) | 2009-04-29 | 2013-01-23 | Trellis Bioscience Llc | IMMUNOREACTIVE ENHANCED ANTIBODIES WITH HEREGULINE COUPLE HER3 |
CN102482345A (zh) | 2009-05-13 | 2012-05-30 | 航道生物技术有限责任公司 | 针对流感病毒的中和分子 |
CA2761280A1 (en) | 2009-05-29 | 2010-12-02 | F. Hoffmann-La Roche Ag | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
US9050341B2 (en) * | 2009-07-14 | 2015-06-09 | Natco Pharma Limited | Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives |
EP2488199A1 (en) | 2009-10-14 | 2012-08-22 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
LT3351558T (lt) * | 2009-11-13 | 2020-06-10 | Daiichi Sankyo Europe Gmbh | Medžiaga ir būdai, skirti su her-3 susijusių ligų gydymui ir prevancijai |
CA2781682A1 (en) | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Multispecific antibodies, antibody analogs, compositions, and methods |
HUE029026T2 (en) | 2009-12-22 | 2017-01-30 | Roche Glycart Ag | Anti-HER3 antibodies and their applications |
WO2011112953A2 (en) | 2010-03-11 | 2011-09-15 | Merrimack Pharmaceuticals, Inc. | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
US8481687B2 (en) | 2010-04-09 | 2013-07-09 | Aveo Pharmaceuticals, Inc. | Anti-ErbB3 antibodies |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
US8741288B2 (en) * | 2010-07-07 | 2014-06-03 | Chang Gung Medical Foundation, Linkou Branch | Protein markers for detecting liver cancer and method for identifying the markers thereof |
BR112013004012B1 (pt) | 2010-08-20 | 2021-03-23 | Novartis Ag | Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
JP5766296B2 (ja) | 2010-12-23 | 2015-08-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用 |
CA2828075A1 (en) | 2011-03-11 | 2012-09-20 | Merrimack Pharmaceuticals, Inc. | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |
KR101517320B1 (ko) | 2011-04-19 | 2015-05-28 | 메리맥 파마슈티컬즈, 인크. | 단일특이적 및 이중특이적 항-igf-1r 및 항 erbb3 항체 |
US9346883B2 (en) | 2011-05-13 | 2016-05-24 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antibodies against HER3 |
JP6468838B2 (ja) | 2011-05-19 | 2019-02-13 | ラボラトリー コーポレイション オブ アメリカ ホールディングス | 癌患者の生存可能性を決定するためおよび癌患者における転移可能性を予測するための方法 |
CA2840461A1 (en) | 2011-06-20 | 2012-12-27 | Kyowa Hakko Kirin Co., Ltd. | Anti-erbb3 antibody |
US10300140B2 (en) | 2011-07-28 | 2019-05-28 | I2 Pharmaceuticals, Inc. | Sur-binding proteins against ERBB3 |
EP2751285B2 (en) | 2011-08-31 | 2020-04-01 | Genentech, Inc. | Method for sensitivity testing of a tumour for a egfr kinase inhibitor |
US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
IN2014CN03042A (ja) | 2011-09-30 | 2015-07-03 | Regeneron Pharma | |
CN103959065B (zh) | 2011-10-06 | 2018-07-17 | Aveo制药公司 | 预测肿瘤对抗erbb3抗体的应答 |
CN116271013A (zh) | 2011-10-14 | 2023-06-23 | 霍夫曼-拉罗奇有限公司 | Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品 |
DK2797957T3 (da) | 2011-11-23 | 2019-09-23 | Medimmune Llc | Bindingsmolekyler specifikke for her3 og anvendelser deraf |
WO2013081645A2 (en) | 2011-11-30 | 2013-06-06 | Genentech, Inc. | Erbb3 mutations in cancer |
WO2013084147A2 (en) | 2011-12-05 | 2013-06-13 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
JP2015500829A (ja) | 2011-12-05 | 2015-01-08 | ノバルティス アーゲー | 上皮細胞増殖因子受容体3(her3)のドメインiiに対するher3の抗体 |
WO2013083810A1 (en) | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
WO2013096828A1 (en) | 2011-12-22 | 2013-06-27 | Sea Lane Biotechnologies, Llc | Surrogate binding proteins |
WO2013124419A1 (en) | 2012-02-23 | 2013-08-29 | U3 Pharma Gmbh | Her3 inhibitor for modulating radiosensitivity |
RU2014136886A (ru) | 2012-03-27 | 2016-05-20 | Дженентек, Инк. | Диагностика и виды лечения, связанные с ингибиторами her3 |
MX2014011925A (es) | 2012-04-02 | 2015-05-11 | Merrimack Pharmaceuticals Inc | Dosificacion y administracion de anticuerpos monoespecíficos y biespecíficos anti- igf 1r y anti erbb3. |
MX363188B (es) | 2012-11-30 | 2019-03-13 | Hoffmann La Roche | Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1. |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
EP2954068B8 (en) | 2013-02-05 | 2018-10-31 | Pierian Holdings, Inc. | Drug selection for non-small cell lung cancer therapy |
RS60026B1 (sr) | 2013-02-18 | 2020-04-30 | Vegenics Pty Ltd | Molekuli koji vezuju ligande i njihove upotrebe |
CN105264382A (zh) | 2013-04-05 | 2016-01-20 | 美国控股实验室公司 | 基于检测her3活化辅助癌症的诊断、预后和治疗的系统和方法 |
CA2910945A1 (en) | 2013-05-08 | 2014-11-13 | Zymeworks Inc. | Bispecific her2 and her3 antigen binding constructs |
US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
MA39776A (fr) | 2014-03-24 | 2017-02-01 | Hoffmann La Roche | Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf |
DK3129063T3 (da) | 2014-04-10 | 2021-04-06 | Daiichi Sankyo Co Ltd | Anti-her3-antistof-lægemiddelkonjugat |
WO2015157634A1 (en) | 2014-04-11 | 2015-10-15 | Kolltan Pharmaceuticals, Inc. | Anti-erbb antibodies and methods of use thereof |
EP3539990B1 (en) | 2014-07-16 | 2021-09-08 | Dana-Farber Cancer Institute, Inc. | Her3 inhibition in low-grade serous cancers |
WO2017014810A1 (en) * | 2015-07-17 | 2017-01-26 | Czerniecki Brian J | Identification of immunogenic mhc class ii peptides for immune-based therapy |
JP2017528430A (ja) | 2014-07-17 | 2017-09-28 | ブライアン ジェイ ツェルニキCZERNIECKI, Brian, J. | 免疫に基づく療法のための、免疫原性mhcクラスiiペプチドの同定 |
US10689459B2 (en) | 2014-12-12 | 2020-06-23 | Novartis Ag | Treatment of breast cancer brain metastases |
WO2016196377A1 (en) | 2015-05-29 | 2016-12-08 | Merrimack Pharmaceuticals, Inc. | Combination cancer therapies |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
AU2016286898B2 (en) | 2015-06-29 | 2022-12-08 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
US20170233491A1 (en) | 2016-01-19 | 2017-08-17 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of combination therapies comprising istiratumab, uses and methods of treatment |
MX2018011054A (es) | 2016-03-15 | 2019-01-21 | Merrimack Pharmaceuticals Inc | Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3. |
EP3454863A1 (en) | 2016-05-10 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
TW201828993A (zh) | 2016-12-12 | 2018-08-16 | 日商第一三共股份有限公司 | 抗體-藥物結合物與免疫檢查點抑制劑之組合 |
TW201827077A (zh) | 2016-12-28 | 2018-08-01 | 美商建南德克公司 | 晚期her2表現癌症之治療 |
LT3570884T (lt) | 2017-01-17 | 2020-12-10 | Genentech, Inc. | Poodinės her2 antikūnų kompozicijos |
KR102537651B1 (ko) | 2017-01-17 | 2023-05-26 | 다이이찌 산쿄 가부시키가이샤 | 항 gpr20 항체 및 항 gpr20 항체-약물 콘쥬게이트 |
AU2018227788B2 (en) | 2017-03-02 | 2021-04-22 | F. Hoffmann-La Roche Ag | Adjuvant treatment of HER2-positive breast cancer |
WO2018200505A1 (en) | 2017-04-24 | 2018-11-01 | Genentech, Inc. | Erbb2/her2 mutations in the transmbrane or juxtamembrane domain |
TW202330036A (zh) | 2017-05-15 | 2023-08-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物之製造方法 |
CA3063747C (en) * | 2017-06-02 | 2023-01-03 | Etubics Corporation | Compositions and methods for tumor vaccination and immunotherapy involving her antigens |
CN117838881A (zh) | 2017-08-31 | 2024-04-09 | 第一三共株式会社 | 制备抗体-药物缀合物的新方法 |
KR20200041993A (ko) | 2017-08-31 | 2020-04-22 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 개량 제조 방법 |
CN117815404A (zh) | 2018-05-18 | 2024-04-05 | 第一三共株式会社 | 抗-muc1抗体-药物缀合物 |
AU2020456731A1 (en) | 2020-06-29 | 2023-01-05 | F. Hoffmann-La Roche Ag | Pertuzumab plus trastuzumab fixed dose combination |
EP4180061A1 (en) | 2021-11-10 | 2023-05-17 | Nerviano Medical Sciences S.r.l. | Anthracycline derivative linker reagents, antibody-drug conjugates and methods |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4867973A (en) * | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
US4480968A (en) * | 1984-04-05 | 1984-11-06 | General Motors Corporation | Two-cycle engine compressor |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
GB8810400D0 (en) * | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
GB8910977D0 (en) | 1989-05-12 | 1989-06-28 | Rolls Royce Plc | Metal matrix composite material |
US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
CA2037440A1 (en) * | 1990-03-02 | 1991-09-03 | Gregory D. Plowman | Her3: a novel egf receptor homolog |
-
1989
- 1989-12-01 US US07/444,406 patent/US5183884A/en not_active Expired - Lifetime
-
1990
- 1990-11-30 CA CA002069900A patent/CA2069900C/en not_active Expired - Lifetime
- 1990-11-30 DE DE69032133T patent/DE69032133T2/de not_active Expired - Lifetime
- 1990-11-30 AU AU68899/91A patent/AU654805B2/en not_active Expired
- 1990-11-30 WO PCT/US1990/007025 patent/WO1991008214A1/en active IP Right Grant
- 1990-11-30 ES ES91900108T patent/ES2113877T3/es not_active Expired - Lifetime
- 1990-11-30 JP JP50088591A patent/JP3196079B2/ja not_active Expired - Lifetime
- 1990-11-30 EP EP91900108A patent/EP0502927B1/en not_active Expired - Lifetime
- 1990-11-30 AT AT91900108T patent/ATE163970T1/de not_active IP Right Cessation
- 1990-11-30 DK DK91900108.1T patent/DK0502927T3/da active
-
1992
- 1992-11-10 US US07/978,895 patent/US5480968A/en not_active Expired - Lifetime
-
1995
- 1995-06-07 US US08/475,352 patent/US5916755A/en not_active Expired - Lifetime
- 1995-06-07 US US08/473,119 patent/US5820859A/en not_active Expired - Lifetime
-
1998
- 1998-10-13 US US09/170,699 patent/US6639060B1/en not_active Expired - Lifetime
-
2001
- 2001-03-23 JP JP2001085000A patent/JP3632171B2/ja not_active Expired - Lifetime
-
2003
- 2003-10-24 US US10/693,030 patent/US20040063140A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP0502927A4 (en) | 1993-05-26 |
DE69032133T2 (de) | 1998-07-02 |
EP0502927A1 (en) | 1992-09-16 |
ES2113877T3 (es) | 1998-05-16 |
AU654805B2 (en) | 1994-11-24 |
US20040063140A1 (en) | 2004-04-01 |
JP3632171B2 (ja) | 2005-03-23 |
AU6889991A (en) | 1991-06-26 |
US5916755A (en) | 1999-06-29 |
EP0502927B1 (en) | 1998-03-11 |
WO1991008214A1 (en) | 1991-06-13 |
JP3196079B2 (ja) | 2001-08-06 |
JP2001299373A (ja) | 2001-10-30 |
US5820859A (en) | 1998-10-13 |
CA2069900A1 (en) | 1991-06-02 |
US5480968A (en) | 1996-01-02 |
ATE163970T1 (de) | 1998-03-15 |
US6639060B1 (en) | 2003-10-28 |
DE69032133D1 (de) | 1998-04-16 |
DK0502927T3 (da) | 1998-06-02 |
US5183884A (en) | 1993-02-02 |
CA2069900C (en) | 2004-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06503467A (ja) | 上皮増殖因子受容体に関連する受容体のための遺伝子をコードしているdnaセグメント | |
US6599709B1 (en) | Method for screening for soluble ligands to a receptor-type tyrosine kinase | |
JPH10512440A (ja) | サイトカイン”lerk−7” | |
US6608181B2 (en) | Fibroblast growth factor receptor activating gene I and related compositions and methods | |
JPH06501381A (ja) | ヒトマクロファージ炎症性タンパク質2α | |
US8703917B2 (en) | Epidermal growth factor receptor variants and pharmaceutical compositions thereof | |
Feldman et al. | A highly efficient retroviral vector allows detection of the transforming activity of the human c-fps/fes proto-oncogene | |
EP0646129A1 (en) | Receptor-type tyrosine kinase-like molecules | |
US8796421B2 (en) | Human epidermal growth factor receptor variant lacking an exon | |
US7544485B2 (en) | Baldness related gene and the polypeptide encoded thereby, and uses | |
US20120288876A1 (en) | Novel identified oncogene with kinase-domain (nok) | |
US7037683B2 (en) | Human longevity assurance protein, its coding sequence and their use | |
CN1418223A (zh) | 新的人肝癌相关蛋白及其编码序列 | |
KR100472747B1 (ko) | 인간 원암 유전자 및 이에 의해 코드되는 단백질 | |
WO2001032699A1 (fr) | Nouveau polypeptide, nouvelle udp glucose-glycoproteine glucosyltransferase (« biohugtr »), et polynucleotide codant pour ce polypeptide | |
US20060110737A1 (en) | Human tumor-associated gene ct120 on chromosome 17p 13.3 region and the protein encoded by it | |
CN1952165A (zh) | pp3774基因在抑制细胞生长中的应用 | |
CN1982455A (zh) | 抑制Wnt活性的多核苷酸及其编码多肽和用途 | |
AU4050593A (en) | Receptor-type tyrosine kinase-like molecules | |
WO2002074919A2 (en) | Protein-protein interactions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080608 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090608 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090608 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100608 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100608 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110608 Year of fee payment: 10 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110608 Year of fee payment: 10 |